Retension Pharmaceuticals Inc. (RTSN) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Retension Pharmaceuticals Inc. (NASDAQ: RTSN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $11.36 (-3.97% 1D, market cap $93.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, RTSN ranks #326 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RTSN carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COYA (Coya Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $93.4M) and NTHI (NeOnc Technologies Holdings Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $92.9M). Among the 5-stock peer group, RTSN leads on earnings multiple (N/A) while COYA leads on capital efficiency (-35.0% ROIC).
For Retension Pharmaceuticals Inc. (RTSN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #326 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($2.6M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While RTSN currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.72) and Max Pain ($11.93) forces dealer call-delta covering toward $19.57.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Retension Pharmaceuticals Inc. (RTSN) dropped -3.97% to $11.36, trading at 19% of its 52-week range ($9.66 – $18.64). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Yahoo Finance UK report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
Preview next weekâs market movers: jobs data, PMI reports, major earnings from Apple and AMD, and IPO buzz. Read here for more details.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RTSN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RTSN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Retension Pharmaceuticals Inc. (RTSN) ranks #326 by composite RQD confidence (48/100, grade D) and #671 by equity capitalization ($93.2M). Within this direct 5-issuer industry benchmark cohort, RTSN leads on earnings valuation at N/A trailing P/E, while COYA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RTSN currently leads its immediate peer cohort in composite quantitative strength at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RTSN
ACTIVE
Retension Pharmaceuticals Inc. | D | 48/100 | — | — | — | -3.97% | $93.2M | Benchmark Subject |
| COYA Coya Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -9.30% | $93.4M | /coya-vs-rtsn → |
| NTHI NeOnc Technologies Holdings Inc. | E | 33/100 | — | — | -35.0% | +4.49% | $92.9M | /nthi-vs-rtsn → |
| PLYX Polaryx Therapeutics Inc. | E | 31/100 | — | — | -35.0% | -5.91% | $92.7M | /plyx-vs-rtsn → |
| GNLX Genelux Corporation | E | 29/100 | — | — | -35.0% | -0.95% | $95.0M | /gnlx-vs-rtsn → |
Retension Pharmaceuticals Inc. (RTSN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $93.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-02, Retension Pharmaceuticals Inc. (NASDAQ: RTSN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $11.36 (-3.97% 1D, market cap $93.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, RTSN ranks #326 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RTSN carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COYA (Coya Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $93.4M) and NTHI (NeOnc Technologies Holdings Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $92.9M). Among the 5-stock peer group, RTSN leads on earnings multiple (N/A) while COYA leads on capital efficiency (-35.0% ROIC).
For Retension Pharmaceuticals Inc. (RTSN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #326 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
RTSN last traded at $11.36 (-3.97% on volume of 58,853 shares), positioning the stock -10.69% below its 50-day simple moving average ($12.72) and -8.61% below its 200-day simple moving average ($12.43). Across its 52-week range of $9.66 to $18.64, RTSN sits at the 18.9% percentile with a 14-day RSI of 54.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.94 to $12.78).
Why RTSN Stock dropped -3.97% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, RTSN scores 48 out of 100, earning a D grade and the verdict "Roarable Sell — Underperform / Distribution Warning." Across the five pillars, the fundamental cash engine scores 12 of 20 (ROIC 0%; FCF yield 0%), indicating the source data reports no measurable return on invested capital or free-cash-flow yield. Whale/13F flow scores 4 of 20 for institutional accumulation and options positioning, the weakest pillar in the set, meaning the rating reads institutional positioning as unsupportive. Insider conviction scores 9 of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 10 of 20 with a beta of 1.0 and sector sensitivity. Forensic balance sheet scores 13 of 20, supported by an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.
For a prospective investor evaluating the stock today, the upside case rests almost entirely on balance-sheet resilience and a non-negative Piotroski reading, not on current earnings or cash generation, since the source reports zero margins and zero ROIC. The valuation tradeoff is that the source data supplies no P/E, EV/EBITDA, or EPS, so the price of $11.83 cannot be benchmarked against earnings. The distribution warning embedded in the verdict, combined with the weakest pillar being institutional flow, signals that the rating model treats recent positioning as a headwind. This is an analytical framework, not personalized financial advice.
Per the recent news and catalysts section, the most recent headline reports Yahoo Finance UK coverage of RTSN market action, institutional positioning, and fundamental catalysts. Investing.com reports that Retension Pharmaceuticals priced its IPO at $12 per share on Nasdaq. Seeking Alpha reports an upsized IPO priced at $12 per share, with a status flagged as Pending. Moomoo covers stock forecasts and analyst ratings. TradingView reports on average basic shares outstanding. Stock Titan reports that the CEO holds 402,577 common shares alongside options priced from $1.43. All news items carry a YELLOW light and a MARKET WIRE impact label.
Risk watch items include the recent price decline of -9.63% and the IPO-related pricing and upsizing references, which are described in source headlines without further detail. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are reported.
Real-time company headlines, analyst actions, and sector developments for Retension Pharmaceuticals Inc. (RTSN) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance UK report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Retension Pharmaceuticals Inc. (RTSN) market action, institutional positioning, and fundamental catalysts.
Welcome to the RTSN (Retension Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 48/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on RTSN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Retension Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on RTSN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $11.83 (52-wk range $11.12 - $13.73), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).